REPLIGEN CORP Proceeds from (Payments for) Other Financing Activities
REPLIGEN CORP (RGEN) reported Proceeds from (Payments for) Other Financing Activities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2026-02-26
- REPLIGEN CORP proceeds from (payments for) other financing activities for the quarter ending 2025-06-30 was $0.00.
- REPLIGEN CORP proceeds from (payments for) other financing activities for the quarter ending 2025-03-31 was $0.00.
- REPLIGEN CORP proceeds from (payments for) other financing activities for the quarter ending 2024-12-31 was $0.00.
- REPLIGEN CORP proceeds from (payments for) other financing activities for the quarter ending 2024-09-30 was $303.00K.
- REPLIGEN CORP proceeds from (payments for) other financing activities for fiscal 2025 was $0.00.
- REPLIGEN CORP proceeds from (payments for) other financing activities for fiscal 2024 was $0.00.
- REPLIGEN CORP proceeds from (payments for) other financing activities for fiscal 2023 was -$45.00K.
- REPLIGEN CORP proceeds from (payments for) other financing activities for fiscal 2022 was -$26.00K.
| Period end | Proceeds from (Payments for) Other Financing Activities 3 month | Proceeds from (Payments for) Other Financing Activities 6 month | Proceeds from (Payments for) Other Financing Activities 9 month | Proceeds from (Payments for) Other Financing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $303.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-04-29 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $303.00K derived: sum of 3 quarters · filed 2026-02-26 | $137.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $303.00K derived: sum of 2 quarters · filed 2026-02-26 | $137.00K derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $303.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $137.00K derived: sum of 2 quarters · filed 2025-08-07 | $0.00 10-Q · filed 2024-11-18 | -$32.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$303.00K 10-Q · filed 2025-08-07 | -$335.00K derived: sum of 3 quarters · filed 2026-02-26 | -$336.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$137.00K 10-Q · filed 2025-04-29 | -$169.00K derived: sum of 2 quarters · filed 2026-02-26 | -$170.00K derived: sum of 3 quarters · filed 2026-02-26 | -$182.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$33.00K derived: sum of 2 quarters · filed 2026-02-26 | -$45.00K derived: sum of 3 quarters · filed 2026-02-26 | -$45.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-18 | -$13.00K derived: sum of 2 quarters · filed 2024-11-18 | -$13.00K 10-Q · filed 2024-11-18 | |
| 2023-06-30 | -$12.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | -$12.00K 10-Q/A · filed 2024-11-18 | ||
| 2023-03-31 | $0.00 10-Q/A · filed 2024-11-18 | |||
| 2022-12-31 | -$26.00K 10-K · filed 2025-03-14 | |||
| 2021-12-31 | -$21.00K 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |